More US Government validation of IMSC's technology. This is REALLY BIG IMO! This should open up new channels of demand for a multiple of applications worldwide. Waiting on a nice PR from this news.

$IMSC - Implant Sciences technology validated by US Government/NIST:

https://www.fbo.gov/?s=opportunity&mode=form&id=6e1f259df994aa7f7b55ca00f27165ad&tab=core&_cview=0

$IMSC - Implant Sciences technology validated by US Government/NIST:

https://www.fbo.gov/?s=opportunity&mode=form&id=6e1f259df994aa7f7b55ca00f27165ad&tab=core&_cview=0

$IMSC - Implant Sciences technology validated by US Government/NIST:

https://www.fbo.gov/?s=opportunity&mode=form&id=6e1f259df994aa7f7b55ca00f27165ad&tab=core&_cview=0

$EIPC 0.0089 nanoparticles and RFID tag maker reports first quarter profit as of June 30, 2013:

http://www.otcmarkets.com/financialReportViewer?symbol=EIPC&id=109558

$EIPC 0.0089 nanoparticles and RFID tag maker reports first quarter profit as of June 30, 2013:

http://www.otcmarkets.com/financialReportViewer?symbol=EIPC&id=109558

$EIPC 0.0089 nanoparticles and RFID tag maker reports first quarter profit as of June 30, 2013:

http://www.otcmarkets.com/financialReportViewer?symbol=EIPC&id=109558

Rapiscan Up for Airport Screening Contract Despite Past Controversies

Parent company has ties to the Obama administration

Free Beacon
BY: Alana GoodmanFollow @alanagoodman
August 13, 2013 5:00 am

A technology company with ties to the White House is said to be in the running for a federal airport x-ray screener contract despite allegations that the company misled the federal government on a contract for controversial full-body scanners that was terminated by the TSA in January.

Rapiscan was accused of falsifying testing data for technology that was supposed to block its full-body scanners from recording nude images of passengers. The company has vehemently denied the allegations and said the government controlled the test.

“According to information received by the [House Homeland Security Subcommittee on Transportation Security], it appears that the manufacturer may have attempted to defraud the government by knowingly manipulating an operational test,” then-chairman of the subcommittee Rep. Mike Rogers (R-Ala.) wrote in a 2012 letter to the TSA.

The TSA ended its contract with Rapiscan in January, saying the company was not able to complete privacy-protecting software within the imposed deadline.

The Department of Homeland Security also took early steps to block the company from competing for future federal contracts, issuing a “Notice of Proposed Debarment” for Rapiscan in the spring.

Industry observers say Rapiscan is one of the few companies in the running for a multi-million-dollar TSA contract for “X-ray systems for screening passenger carry-on baggage to be used in our Nation’s airports.”

A Rapiscan executive told the Washington Free Beacon he was unable to confirm the company was competing for the contract when reached by phone on Monday.

“As I am sure you understand, we limit what we disclose regarding potential sales opportunities,” Andrew Goldsmith, vice president for global marketing of Rapiscan, said. “However, I can tell you that Rapiscan is eligible to compete for the opportunity you mentioned and we look forward to growing our business with the U.S. government.

Rapiscan’s parent company OSI Systems Inc. is led by Deepak Chopra, not to be confused with the celebrity New Age guru of the same name. Chopra, OSI Systems executive vice president Alan Edrick, and Rapiscan president Ajay Mehra each contributed $2,300 to President Obama’s 2008 campaign, according to campaign finance records.

Chopra accompanied Obama on a trip to India in 2010 to promote U.S.-India business partnerships, according to a press release on the OSI Systems website.

After the DHS Notice of Proposed Debarment, Rapiscan was briefly placed on the government’s excluded parties list, preventing it from competing for contracts, from May 17 to June 21 of this year.

The list includes companies that are “ineligible [to compete for contracts] based upon adequate evidence of conduct indicating a lack of business honesty or integrity, or a lack of business integrity, or regulation, statute, executive order or other legal authority,” pending an investigation.

Companies placed on the excluded parties list can be debarred unless the notice is withdrawn by the DHS or the company and the federal government enter into an “administrative compliance agreement.”

OSI announced that Rapiscan had completed an administrative compliance agreement in June.

“We appreciated the opportunity to meet with DHS and we are pleased to reach this outcome on an important issue for our organization. We take pride in our role as a U.S. Government vendor and this agreement allows us to continue to serve DHS, including TSA, and other U.S. Government agencies as a leading security solutions provider.”

The TSA did not respond to questions about the details of the mediation agreement or Rapiscan’s potential bid as of press time.

©2013 All Rights Reserved

$IMSC - Implant Sciences Sponsors Global Sports Summit - Yahoo! Finance

WILMINGTON, MA--(Marketwired - Aug 13, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it sponsored and attended The Global Sports Summit, the first and only private meeting designed for leaders and owners of sports franchises from the NFL, NBA, MLB, NHL, MLS, European Football and other professional sports globally. On August 4th through 6th in Aspen, Colorado, Implant Sciences was a Session Host Sponsor where the Company met with the key decision makers and owners of global sports franchises.

"We see a very clear opportunity for our explosives trace detectors to meet the specific needs of security providers for sporting venues and events," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "At the different sports industry related conferences we have attended over the past few months we have provided product demonstrations and been in advanced discussions with the owners and managers of major sports venues and their security providers."

Implant Sciences' QS-H150 handheld explosives trace detectors have already provided fast, effective, user-friendly, radiation-free, non-invasive, and cost-efficient screening at some of the world's largest sporting events including the 2008 Beijing Olympics, the 2011 Summer Universiade Games in Shenzhen, China, and the 2012 Special Olympics in London.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

http://finance.yahoo.com/news/implant-sciences-sponsors-global-sports-110000718.html

$IMSC - Implant Sciences Sponsors Global Sports Summit - Yahoo! Finance

WILMINGTON, MA--(Marketwired - Aug 13, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it sponsored and attended The Global Sports Summit, the first and only private meeting designed for leaders and owners of sports franchises from the NFL, NBA, MLB, NHL, MLS, European Football and other professional sports globally. On August 4th through 6th in Aspen, Colorado, Implant Sciences was a Session Host Sponsor where the Company met with the key decision makers and owners of global sports franchises.

"We see a very clear opportunity for our explosives trace detectors to meet the specific needs of security providers for sporting venues and events," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "At the different sports industry related conferences we have attended over the past few months we have provided product demonstrations and been in advanced discussions with the owners and managers of major sports venues and their security providers."

Implant Sciences' QS-H150 handheld explosives trace detectors have already provided fast, effective, user-friendly, radiation-free, non-invasive, and cost-efficient screening at some of the world's largest sporting events including the 2008 Beijing Olympics, the 2011 Summer Universiade Games in Shenzhen, China, and the 2012 Special Olympics in London.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

http://finance.yahoo.com/news/implant-sciences-sponsors-global-sports-110000718.html

$IMSC - Implant Sciences Sponsors Global Sports Summit - Yahoo! Finance

WILMINGTON, MA--(Marketwired - Aug 13, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it sponsored and attended The Global Sports Summit, the first and only private meeting designed for leaders and owners of sports franchises from the NFL, NBA, MLB, NHL, MLS, European Football and other professional sports globally. On August 4th through 6th in Aspen, Colorado, Implant Sciences was a Session Host Sponsor where the Company met with the key decision makers and owners of global sports franchises.

"We see a very clear opportunity for our explosives trace detectors to meet the specific needs of security providers for sporting venues and events," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "At the different sports industry related conferences we have attended over the past few months we have provided product demonstrations and been in advanced discussions with the owners and managers of major sports venues and their security providers."

Implant Sciences' QS-H150 handheld explosives trace detectors have already provided fast, effective, user-friendly, radiation-free, non-invasive, and cost-efficient screening at some of the world's largest sporting events including the 2008 Beijing Olympics, the 2011 Summer Universiade Games in Shenzhen, China, and the 2012 Special Olympics in London.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

http://finance.yahoo.com/news/implant-sciences-sponsors-global-sports-110000718.html

Terror alert spurs extra screening of cargo flown into U.S.
Security Clearance
By Mike M. Ahlers
August 6, 2013 - 10:30 PM ET

All in-bound cargo on commercial flights from Europe, the Middle East, and Africa - and quite possibly other areas of the world - is getting screened twice, as a result of the recent terror threats, according to a cargo industry official.

The Department of Homeland Security late last week ordered airlines to increase inspections of cargo at the last point of departure for the United States, said Brandon Fried, executive director of Airforwarders Association, a trade group.

"They said, until further notice, this is what you're going to do," Fried said.

"Nothing unscreened gets on the plane," Fried said. "Basically they said, 'If you used one method, or several methods (of inspecting cargo), you need to do it again. It's redundant, dual screening."

This is in IMSC's wheel-house. It's time to sit tight and wait for Mr. Market to discover this.

Liquid explosives on terrorists' clothing a new concern:

Officials fear al-Qa'ida may have developed new liquid explosive as US urges all citizens to leave Yemen

Liquid explosive could potentially be dipped onto clothes to make them explosive when dry

The Independent
By Heather Saul
Tuesday 06 August 2013

Senior US officials have voiced growing concerns that al-Qa'ida may have developed a liquid explosive that could be undetectable under current security systems whilst the military has evacuated its non-essential government personnel from Yemen.

An explosive liquid developed to be dipped onto ordinary clothing, becoming explosive when dry, could be used in a potential attack, according to two senior government officials briefed on the terror threat that has prompted the closure of nearly two dozen US embassies.

Another senior official has reportedly said that it may not be detectable under the current security measures.

The new technique is believed to have been developed by Yemen-based al-Qa'ida affiliate al Qaeda in the Arabian Peninsula (AQAP), of which bomb-maker Ibrahim al-Asiri is associated.

Al-Asiri is thought to have masterminded explosive devices such as the underwear bomb and surgically implanted body bombs.

Transportation Security Administration boss John Pistole expressed concerns in July over an improved version of the underwear bomb that may have been developed.

However, the TSA refused to comment on the liquid devices, although an official spokesperson said: "As always, our security posture, which at all times includes a number of measures both seen and unseen, will continue to respond appropriately to protect the American people from an ever evolving threat picture.“

“I am not in a position to discuss any intelligence around this current threat. But, as a general matter TSA screens both passengers and carry-on baggage for metallic and non-metallic prohibited items, including weapons and explosives. To do this, TSA uses the best available imaging technology to safely screen passengers for any concealed items."

Concerns come as the US government urged all American citizens to leave Yemen immediately for fear of possible attacks. Department of State officials said they had intercepted a conversation between the head of al-Qa'ida and his deputy in Yemen detailing plans of a major terror attack.

That intelligence led to the closure of embassies across the region, as well as a warning to all international travellers of a perceived “high security threat level”.

The State Department said it ordered the evacuation of non-essential government personnel "due to the continued potential for terrorist attacks" and said US citizens in Yemen should leave immediately because of an "extremely high" security threat level.

Defence Department press secretary George Little said the US Air Force transported State Department personnel out of Sanaa early today, adding: "The US Department of Defence continues to have personnel on the ground in Yemen to support the US State Department and monitor the security situation."

The Foreign Office also announced that it had evacuated all staff from its embassy in Yemen due to security concerns. The office said the staff were "temporarily withdrawn to the UK", but declined further comment. Previously, the UK had said the embassy would be closed until the end of the Muslim festival of Eid later this week.

$IMSC - Implant Sciences bullish case:

http://seekingalpha.com/article/1598522-implant-sciences-sometimes-facts-lie?source=google_

$IMSC - Implant Sciences bullish case:

http://seekingalpha.com/article/1598522-implant-sciences-sometimes-facts-lie?source=google_

$IMSC - Implant Sciences bullish case:

http://seekingalpha.com/article/1598522-implant-sciences-sometimes-facts-lie?source=google_news

Nice job, Sully. This morning on Seeking Alpha:

http://seekingalpha.com/article/1598522-implant-sciences-sometimes-facts-lie?source=google_news

Security worries trigger embassy closings

CNN - August 1, 2013 - 07:16 PM ET

The State Department will close a number of US embassies and consulates this Sunday, Aug. 4, due to "more than the usual chatter" about a potential terrorist threat.

A Senior US official said while the threat does not have a great deal of specificity about time and location, but it is being taken 'very seriously."

US 'interests" including military installations could also see additional security and protection measures. This official, and a second official as well, noted the date comes as tensions are rising with the approach of both the holy days at the end of Ramadan and the one year anniversary of the September 11th attack on the US compound in Benghazi.

There are several hundred Marines in Spain, Italy and in the Red Sea that could assist in providing additional security for US embassies in Southern Europe, North Africa or the Middle East if requested by the State Department.

State Department spokeswoman Marie Harf revealed the closing but gave no details as to the location of the impacted embassies or the nature of the threat.

"The Department of State has instructed certain U.S. embassies and consulates to remain closed or to suspend operations on Sunday,August 4th. The department has been apprised of information that out of an abundance of caution and care for our employees and others who may be visiting our installation, that indicates we should institute these precautionary steps. The department, when conditions warrant, takes steps like this to balance our continued operations with security and safety," Harf said at the State Department briefing with reporters.

Implant Sciences has record year, doubles office space
Boston Business Journal
Jul 30, 2013

Implant Sciences Corp. has doubled its space at 500 Research Drive in Wilmington, Mass.

Implant Sciences Corp.(OTCQB: IMSC) had a record 2013 shipping more units than ever before, the company said. That growth, coupled with a number of new contracts, has led to a doubling of its office space.

The Wilmington, Mass.-based developer of systems for homeland security has moved its headquarters and manufacturing facility into a new 58,000-square-foot facility located in the same technology park as its previous office. The new space, at 500 Research Drive Unit 3 in an 85-acre park in Wilmington, is double the size of its old one, according to the company.

CEO Glenn Bolduc said the move was necessary to support its growth.

“As we continue to advance our certification efforts both here in the U.S. and internationally, we expect growing sales. Expanding our Massachusetts facility underscores our commitment to manufacturing high-tech equipment right here in the USA,” Bolduc said in a statement. “I’m very proud of everything the entire Implant Sciences team has accomplished to bring us to this point, and look forward to continued growth in the future.”

In fiscal year 2013, Implant Sciences built and shipped more units than ever before in its history, according to Brenda Baron, vice president of manufacturing. Implant’s explosive detection systems were used in recent weeks at screening points at Queen Elizabeth II’s birthday celebration, he said.

For more on the birthday bash, click here. Before that, Implant won a Middle East defense contract selling four of its Quantum Sniffer QS-H150. The handheld explosive detection systems were sold by Implant’s Bahrain-based, international distributor Building Defense Systems (BDS).

More ETD contracts for Indian airport security could be in the cards for IMSC based on this new report:

Small airports across India face major security threats

Daily Online India
By Vikas Mishra
PUBLISHED: 17:02 EST, 30 July 2013

Inadequate surveillance devices, broken X-ray machines, shortage of wireless sets and illegal constructions make a mockery of the security arrangements in several smaller airports across the country.

The Bureau of Civil Aviation Security (BCAS) has found some major faults in the security systems at airports in Bhuj, Aurgangabad, Bhopal, Juhu, Kanpur and Imphal.

The bureau recently wrote to the Airports Authority of India (AAI) chairman flagging the issue. The letter has gone into the specifics of the problems faced by these airports.

In Bhuj, the bureau has found that the departure gate of the airport doesn't have an explosive trace detector and hand-held metal detectors.

The bureau said the CCTV cameras at Bhuj did not have adequate capacity to store a month's footage.

The Aurangabad airport urgently needs 58 CCTV cameras and its perimeter wall needs to be repaired.

In Bhopal, a slum near the new terminal building has become a security threat because of the presence of anti-social elements there, particularly drug traffickers.

In Bhopal, a slum near the new terminal building has raised security fears thanks to the presence of drug traffickersIn Bhopal, a slum near the new terminal building has raised security fears thanks to the presence of drug traffickers
In Bhopal, a slum near the new terminal building has raised security fears thanks to the presence of drug traffickers

The bureau also pointed out that the state police and the CISF were at loggerheads on the security arrangements. Even bomb disposal and sniffer dog squads are not available with the CISF or the AAI at Bhopal. Stray animals frequent the premises.

In Mumbai's Juhu aerodrome, the bureau noticed that no-objection certificates (NOCs) were issued to developers for the construction of 100 buildings in the vicinity of the airfield. The CBI is also looking into the anomaly as high-rise building posed risks to the airport, because of which the runway may have to be shut.

The bureau stated that J.M.S Negi, executive, air traffic management, AAI (Mumbai) and B.K. Dutta, general manager (NOC), were involved in giving the go-ahead to the builders. A vigilance probe is underway in the matter.

The letter also stated that in Kanpur airport, the X-ray machine that screens the registered baggage, has not been calibrated properly posing a threat to the aviation security.

The report said the machine was not fit for carrying out important tests such as the single-wire resolute test.

http://www.dailymail.co.uk/indiahome/indianews/article-2381597/Small-airports-India-face-major-security-threats.html#ixzz2aaHPlgaG

$IMSC - Implant Sciences Moves Into 58,000 sq. ft. Manufacturing & Office Facility to Accommodate Anticipated Demand

WILMINGTON, MA--(Marketwired - Jul 30, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has moved its headquarters and manufacturing operations to 500 Research Drive Unit 3, Wilmington, Massachusetts 01887. The new 58,000 square foot facility, located in the same technology park as its prior location, offers the Company more than double its previous space. Implant Sciences' telephone and fax numbers remain the same, phone: 978-752-1700, fax: 978-752-1711.

"As we continue to advance our certification efforts both here in the U.S. and internationally, we expect growing sales. Expanding our Massachusetts facility underscores our commitment to manufacturing high-tech equipment right here in the USA," stated Implant Sciences' President and CEO Glenn D. Bolduc. "I'm very proud of everything the entire Implant Sciences team has accomplished to bring us to this point, and look forward to continued growth in the future."

Brenda Baron, Vice President of Manufacturing for Implant Sciences, added, "In FY2013, Implant Sciences built and shipped more units than ever before in its history. I'm very proud of what the manufacturing team was able to accomplish. This new facility is critical to supporting continued growth in sales."

"Since manufacturing requirements were paramount in our need for a new facility, Brenda was in charge of planning and executing the move," added Dr. William McGann, Chief Operations Officer for Implant Sciences. "She and her team did an amazing job, relocating all of Implant Sciences with minimal downtime."

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

http://finance.yahoo.com/news/implant-sciences-moves-58-000-110000065.html

$IMSC - Implant Sciences Moves Into 58,000 sq. ft. Manufacturing & Office Facility to Accommodate Anticipated Demand

WILMINGTON, MA--(Marketwired - Jul 30, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has moved its headquarters and manufacturing operations to 500 Research Drive Unit 3, Wilmington, Massachusetts 01887. The new 58,000 square foot facility, located in the same technology park as its prior location, offers the Company more than double its previous space. Implant Sciences' telephone and fax numbers remain the same, phone: 978-752-1700, fax: 978-752-1711.

"As we continue to advance our certification efforts both here in the U.S. and internationally, we expect growing sales. Expanding our Massachusetts facility underscores our commitment to manufacturing high-tech equipment right here in the USA," stated Implant Sciences' President and CEO Glenn D. Bolduc. "I'm very proud of everything the entire Implant Sciences team has accomplished to bring us to this point, and look forward to continued growth in the future."

Brenda Baron, Vice President of Manufacturing for Implant Sciences, added, "In FY2013, Implant Sciences built and shipped more units than ever before in its history. I'm very proud of what the manufacturing team was able to accomplish. This new facility is critical to supporting continued growth in sales."

"Since manufacturing requirements were paramount in our need for a new facility, Brenda was in charge of planning and executing the move," added Dr. William McGann, Chief Operations Officer for Implant Sciences. "She and her team did an amazing job, relocating all of Implant Sciences with minimal downtime."

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

http://finance.yahoo.com/news/implant-sciences-moves-58-000-110000065.html

$IMSC - Implant Sciences Moves Into 58,000 sq. ft. Manufacturing & Office Facility to Accommodate Anticipated Demand

WILMINGTON, MA--(Marketwired - Jul 30, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has moved its headquarters and manufacturing operations to 500 Research Drive Unit 3, Wilmington, Massachusetts 01887. The new 58,000 square foot facility, located in the same technology park as its prior location, offers the Company more than double its previous space. Implant Sciences' telephone and fax numbers remain the same, phone: 978-752-1700, fax: 978-752-1711.

"As we continue to advance our certification efforts both here in the U.S. and internationally, we expect growing sales. Expanding our Massachusetts facility underscores our commitment to manufacturing high-tech equipment right here in the USA," stated Implant Sciences' President and CEO Glenn D. Bolduc. "I'm very proud of everything the entire Implant Sciences team has accomplished to bring us to this point, and look forward to continued growth in the future."

Brenda Baron, Vice President of Manufacturing for Implant Sciences, added, "In FY2013, Implant Sciences built and shipped more units than ever before in its history. I'm very proud of what the manufacturing team was able to accomplish. This new facility is critical to supporting continued growth in sales."

"Since manufacturing requirements were paramount in our need for a new facility, Brenda was in charge of planning and executing the move," added Dr. William McGann, Chief Operations Officer for Implant Sciences. "She and her team did an amazing job, relocating all of Implant Sciences with minimal downtime."

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

http://finance.yahoo.com/news/implant-sciences-moves-58-000-110000065.html

More proof that the ETD business means war: looking at IMSC's Twitter account Smiths Detection is following IMSC while IMSC is following Rapiscan Systems!

From IMSC's Twitter account: BORLAS becomes distributor of Implant Sciences' QS-B220 & QS-H150 detectors in Russia, Ukraine, Kazakhstan http://bit.ly/14LH5gS

$IMSC - Open the dam gates and let the orders flow in! This is the 2nd largest order in Implant Science's history and will be surpassed by future larger deals. It is wonderful to be the industry leader with next-generation technology and non-radioactive feature. The future is now!

$IMSC - Open the dam gates and let the orders flow in! This is the 2nd largest order in Implant Science's history and will be surpassed by future larger deals. It is wonderful to be the industry leader with next-generation technology and non-radioactive feature. The future is now!

$IMSC - Open the dam gates and let the orders flow in! This is the 2nd largest order in Implant Science's history and will be surpassed by future larger deals. It is wonderful to be the industry leader with next-generation technology and non-radioactive feature. The future is now!

Open the dam gates and let the orders flow in! This is the 2nd largest order in IMSC's history and will be surpassed by future larger deals. It is wonderful to be the industry leader with next-generation technology and non-radioactive feature. The future is now!

IMSC is In Briefing.com at 7:01AM Eastern.

IMSC is "In Play" this AM.

$IMSC - Implant Sciences Receives Order for $3.5 Million for Explosives Trace Detection Equipment and Supplies - Yahoo! Finance

WILMINGTON, MA--(Marketwired - Jul 18, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has received an order for its Quantum Sniffer™ explosives trace detection equipment and supplies valued at more than $3.5 million. The order is for a combination of QS-H150 handheld and QS-B220 desktop trace detectors. The systems will be delivered over the next several months.

"These orders are a testament to the hard work of the sales team and the quality of our product," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "Any order of this size requires multiple meetings, product demonstrations, and trials. These orders prove that Implant Sciences' next generation technology is exactly what customers around the world have been waiting for."

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About the Quantum Sniffer™ QS-B220 Desktop Explosives and Drugs Trace Detector

The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

http://finance.yahoo.com/news/implant-sciences-receives-order-3-110000583.html

$IMSC - Implant Sciences Receives Order for $3.5 Million for Explosives Trace Detection Equipment and Supplies - Yahoo! Finance

WILMINGTON, MA--(Marketwired - Jul 18, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has received an order for its Quantum Sniffer™ explosives trace detection equipment and supplies valued at more than $3.5 million. The order is for a combination of QS-H150 handheld and QS-B220 desktop trace detectors. The systems will be delivered over the next several months.

"These orders are a testament to the hard work of the sales team and the quality of our product," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "Any order of this size requires multiple meetings, product demonstrations, and trials. These orders prove that Implant Sciences' next generation technology is exactly what customers around the world have been waiting for."

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About the Quantum Sniffer™ QS-B220 Desktop Explosives and Drugs Trace Detector

The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

http://finance.yahoo.com/news/implant-sciences-receives-order-3-110000583.html

$IMSC - Implant Sciences Receives Order for $3.5 Million for Explosives Trace Detection Equipment and Supplies - Yahoo! Finance

WILMINGTON, MA--(Marketwired - Jul 18, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has received an order for its Quantum Sniffer™ explosives trace detection equipment and supplies valued at more than $3.5 million. The order is for a combination of QS-H150 handheld and QS-B220 desktop trace detectors. The systems will be delivered over the next several months.

"These orders are a testament to the hard work of the sales team and the quality of our product," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "Any order of this size requires multiple meetings, product demonstrations, and trials. These orders prove that Implant Sciences' next generation technology is exactly what customers around the world have been waiting for."

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About the Quantum Sniffer™ QS-B220 Desktop Explosives and Drugs Trace Detector

The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

http://finance.yahoo.com/news/implant-sciences-receives-order-3-110000583.html

$CONX - Corgenix Medical Teams Up with Strategic Partners at AACC Clinical Lab Expo 2013

DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (CONX), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners ELITech Group and AXA Diagnostics at the AACC Clinical Lab Expo 2013 in Houston, Texas.

Corgenix will exhibit its AspirinWorks® (11dhTxB2) Test at AACC July 30 – August 1 in booth No. 3009.

Also on display in the Corgenix booth will be the SkyLAB752™ instrument from strategic partner AXA Diagnostics. The Corgenix team will present the new, high-throughput ELISA automated platform, which can process up to 7 microplates simultaneously. The SkyLAB752 is the fastest automated instrument for processing the Corgenix AspirinWorks assay, due to its ability to process up to 384 samples in a single run.

Additionally, Corgenix will have a presence in strategic partner ELITech Group’s booth No. 4707 and 4805, where several Corgenix products will be on display, including the AspirinWorks/11dhTxB2 and Hyaluronic Acid Test Kits. In 2010, the two companies entered into a formal strategic alliance to co-develop new diagnostic tests. The alliance includes an ELITech Group investment in Corgenix and the expansion of Corgenix’ distribution network for its test kits. The Hyaluronic Acid Test Kit has not been cleared or approved for diagnostic use in the Untied States by the US Food and Drug Administration. However, it is CE marked for diagnostic use in the EU.

Corgenix representatives will be available during the conference to answer questions about the AspirinWorks Test and other products, including its diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen, which helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of 11-dehydro thromboxane B2 (11-dhTxB2). High levels of 11-dhTxB2, a metabolite of thromboxane — the target of aspirin therapy — heighten the risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

Millions of Americans take a daily aspirin to prevent heart attack or stroke but don’t know if the aspirin is having the desired effect. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness and therefore reducing the chance of forming a blood clot.

Unlike other functional platelet tests that require freshly drawn blood that must be evaluated in five hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office. Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Contact:.

Corgenix Medical Corp.
Company Contact:
Corgenix Medical Corp.
William Critchfield, 303-453-8903
Senior VP and CFO
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x230
Vice President and Public Relations Supervisor
dan@armadamedical.com

$CONX - Corgenix Medical Teams Up with Strategic Partners at AACC Clinical Lab Expo 2013

DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (CONX), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners ELITech Group and AXA Diagnostics at the AACC Clinical Lab Expo 2013 in Houston, Texas.

Corgenix will exhibit its AspirinWorks® (11dhTxB2) Test at AACC July 30 – August 1 in booth No. 3009.

Also on display in the Corgenix booth will be the SkyLAB752™ instrument from strategic partner AXA Diagnostics. The Corgenix team will present the new, high-throughput ELISA automated platform, which can process up to 7 microplates simultaneously. The SkyLAB752 is the fastest automated instrument for processing the Corgenix AspirinWorks assay, due to its ability to process up to 384 samples in a single run.

Additionally, Corgenix will have a presence in strategic partner ELITech Group’s booth No. 4707 and 4805, where several Corgenix products will be on display, including the AspirinWorks/11dhTxB2 and Hyaluronic Acid Test Kits. In 2010, the two companies entered into a formal strategic alliance to co-develop new diagnostic tests. The alliance includes an ELITech Group investment in Corgenix and the expansion of Corgenix’ distribution network for its test kits. The Hyaluronic Acid Test Kit has not been cleared or approved for diagnostic use in the Untied States by the US Food and Drug Administration. However, it is CE marked for diagnostic use in the EU.

Corgenix representatives will be available during the conference to answer questions about the AspirinWorks Test and other products, including its diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen, which helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of 11-dehydro thromboxane B2 (11-dhTxB2). High levels of 11-dhTxB2, a metabolite of thromboxane — the target of aspirin therapy — heighten the risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

Millions of Americans take a daily aspirin to prevent heart attack or stroke but don’t know if the aspirin is having the desired effect. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness and therefore reducing the chance of forming a blood clot.

Unlike other functional platelet tests that require freshly drawn blood that must be evaluated in five hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office. Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Contact:.

Corgenix Medical Corp.
Company Contact:
Corgenix Medical Corp.
William Critchfield, 303-453-8903
Senior VP and CFO
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x230
Vice President and Public Relations Supervisor
dan@armadamedical.com

$CONX - Corgenix Medical Teams Up with Strategic Partners at AACC Clinical Lab Expo 2013

DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (CONX), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners ELITech Group and AXA Diagnostics at the AACC Clinical Lab Expo 2013 in Houston, Texas.

Corgenix will exhibit its AspirinWorks® (11dhTxB2) Test at AACC July 30 – August 1 in booth No. 3009.

Also on display in the Corgenix booth will be the SkyLAB752™ instrument from strategic partner AXA Diagnostics. The Corgenix team will present the new, high-throughput ELISA automated platform, which can process up to 7 microplates simultaneously. The SkyLAB752 is the fastest automated instrument for processing the Corgenix AspirinWorks assay, due to its ability to process up to 384 samples in a single run.

Additionally, Corgenix will have a presence in strategic partner ELITech Group’s booth No. 4707 and 4805, where several Corgenix products will be on display, including the AspirinWorks/11dhTxB2 and Hyaluronic Acid Test Kits. In 2010, the two companies entered into a formal strategic alliance to co-develop new diagnostic tests. The alliance includes an ELITech Group investment in Corgenix and the expansion of Corgenix’ distribution network for its test kits. The Hyaluronic Acid Test Kit has not been cleared or approved for diagnostic use in the Untied States by the US Food and Drug Administration. However, it is CE marked for diagnostic use in the EU.

Corgenix representatives will be available during the conference to answer questions about the AspirinWorks Test and other products, including its diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen, which helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of 11-dehydro thromboxane B2 (11-dhTxB2). High levels of 11-dhTxB2, a metabolite of thromboxane — the target of aspirin therapy — heighten the risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

Millions of Americans take a daily aspirin to prevent heart attack or stroke but don’t know if the aspirin is having the desired effect. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness and therefore reducing the chance of forming a blood clot.

Unlike other functional platelet tests that require freshly drawn blood that must be evaluated in five hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office. Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Contact:.

Corgenix Medical Corp.
Company Contact:
Corgenix Medical Corp.
William Critchfield, 303-453-8903
Senior VP and CFO
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x230
Vice President and Public Relations Supervisor
dan@armadamedical.com

Explosives-detection research for airport security is topic of DHS briefings next month in D.C.

Military & Aerospace Electronics - July 14, 2013
Posted by John Keller

WASHINGTON, 14 July 2013. Explosives-detection experts at the U.S. Department of Homeland Security (DHS) will brief industry on research efforts in explosives-detection equipment and strategies of finding explosives hidden in checked baggage and carried by airline passengers at airport security checkpoint screening systems next month in Washington.

The DHS Science & Technology branch will conduct the explosive detection industry briefings from 8 a.m. to 6:30 p.m. on 15 and 16 Aug. 2013 at the William J. Cohen Building, 330 C St. S.W., in Washington.

These briefings closely follow industry-day presentations that DHS will conduct on advanced imaging technology (AIT) for aviation security checkpoint and people screening on 13 and 14 Aug. in the same location.

The explosives-detection industry briefings will provide updated project and technology overviews, including mathematical foundations, algorithms, architectures, and hardware, as well as experimental results and future research.

Technical areas related to adaptive compressive measurement and the DARPA Knowledge Enhanced Compressive Measurement (KECoM) program technology will also be included.

This two-day event will have presentations and poster sessions from sponsored researchers. A panel discussion with audience questions is included. Expected government attendees will include staff from DHS S&T Explosives Division (EXD), the Transportation Security Administration (TSA) and other agencies.

Others attending will be from companies in the aviation security business, companies pursuing the aviation security business, companies and organizations with applicable technology including federal labs, universities, and third parties.

DHS is pursuing several research projects to improve explosives-detection capabilities with X-rays. The research seeks to identify novel signatures in different ways from conventional X-ray computed tomography systems and multi-view, dual energy projection scans.

The focus is to enhance capability and probability of improvised explosive threat detection by reducing false alarm rates on several different kinds of improvised explosive threats, while increasing screening throughput, supporting TSA risk-based screening, and reducing equipment life-cycle costs.

Resulting DHS research is expected to define enabling technologies for future screening systems, architectures, components, and detection-and-classification algorithms.

Those who would like to attend should register online no later than 15 July 2013 at www.signup4.net/Public/ap.aspx?EID=AVIA10E. If there are problems registering email DHS's Veronica Leftwich at veronica.leftwich@associates.hq.dhs.gov.

More information is online at https://www.fbo.gov/spg/DHS/OCPO/DHS-OCPO/15-16August2013_Industry_Day/listing.html.

Related stories

-- DHS to brief industry on airport security imaging technology research next month in Washington

-- DHS to brief industry on beefing-up explosives trace detection on 25 and 26 July in Washington

-- Army asks industry to develop complex algorithms for handheld explosives detectors.

$IMSC - Implant Sciences’ explosive trace detection system clears a key TSA testing hurdle

Government Security News - Fri, 2013-07-12 04:19 PM
By: Jacob Goodwin

Implant Sciences Corp., a high technology supplier of systems and sensors for homeland security and defense markets, announced on July 9 that its QS-B220 desktop explosives trace detection system has successfully completed Independent Testing and Evaluation (IT&E) by TSA. The device still has several more hurdles to clear before it can be added to TSA’s approved product list for use in passenger screening.

The QS-B220 passed TSA's detection portion of qualification testing for checkpoint screening and is now testing at the TSA Systems Integration Facility (TSIF). “The ITE is the long pole in the tent for the overall approval,” said Glenn Bolduc, Implant Sciences' president and CEO, during a telephone interview with Government Security News. “We believe this is the big test.”

"TSA checkpoint qualification is ranked amongst the most stringent explosives trace detection qualifications around the world," said Glenn Bolduc, Implant Sciences' president and CEO. “Completion of this phase of the qualification process is the single greatest achievement in this company's history. This marks us as the only company to have ever passed IT&E for the ETD checkpoint qualification using IMS with a non-radioactive source. We are extremely proud of our team's effort, dedication, and efficient execution."

Bolduc told GSN he hopes that this device will have passed all of TSA’s required tests by the end of 2013. If and when TSA approves the Implant Sciences device for use in passenger screening, it could open a huge domestic market for the company, said Bolduc. “It’s in the hundreds of millions of dollars,” he estimated.

"Our Company has built a product that truly deserves to be called the new standard in trace detection," added Darryl Jones, vice president of sales and marketing at the company. "Our progress in this qualification means we are one step closer towards participating in future tenders for the Department of Homeland Security. Furthermore, it also positions us to participate in procurements and tenders globally that look to this qualification as a prerequisite."

The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products, said the company in a news release.

Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use, the news release adds.